You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.
Fluidigm's Biomark HD microfluidic platform will enable more than 180,000 real-time PCR tests to be run over the next 90 days to potentially support COVID-19 screening.
In October the company received $15 million in funding from BARDA and venture capital firms to advance its early sepsis detection technology.
The company said the financing brings it a step closer to fulfilling its vision of enabling new-generation tissue analytics tests based on its microfluidic technology.
The funding will support up to 90 percent of development costs for the Klaris system, which purportedly performs phenotypic testing in four hours.
Uppsala University spinout Astrego has developed a system to rapidly detect bacterial infection and antibiotic susceptibility in biofluid.
The firm said that its panel enables receipt of results for life-threatening conditions, such as sepsis and bacteremia, within about 11 minutes at the point of care.
The tubes and collection kits meet the requirements of the European In-Vitro Diagnostic Devices Directive, and the company can now commercialize the devices throughout Europe.
Akadeum is currently developing a tool that involves microbubbles to deplete background molecules from circulating tumor cells in liquid biopsies.
The firm will use the net proceeds for research and development, marketing, and general corporate purposes to help commercialize its LX Analyzer technology.